ArticleCureus2025
Polymyalgia Rheumatica and Giant Cell Arteritis: A Geriatric Perspective.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomarkers of Inflammaging and Cellular Senescence in Musculoskeletal (MSK) Diseases: The Knowns and the Unknowns.Biomedicines · 2026Article
- Time to remission and steroid doses in older and younger patients with polymyalgia rheumatica.European geriatric medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsPolymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are inflammatory disorders predominantly affecting older adults. PMR is primarily characterized by proximal muscle pain and systemic inflammation, while GCA involves large-vessel inflammation, posing risks of vision loss and stroke. Due to overlapping clinical features and age-related prevalence, diagnosing these conditions remains challenging. While PMR is largely diagnosed based on clinical symptoms and laboratory markers, GCA often requires histopathological confirmation via temporal artery biopsy (TAB). This study aims to assess the clinical presentation, diagnostic approaches, and treatment outcomes of PMR and GCA in geriatric patients, emphasizing the role of clinical versus laboratory and histopathological diagnosis. MATERIALS AND
methodsA cross-sectional study was conducted at Khyber Teaching Hospital, Peshawar, Pakistan, from September 2023 to September 2024, involving 118 patients aged 50 years or older diagnosed with PMR and/or GCA. Data were collected through patient interviews, medical records, and diagnostic reports. Statistical analyses were performed to evaluate clinical characteristics, laboratory markers, and treatment responses.
resultsThe mean age of participants was 68.5 ± 7.4 years, with 65% female. PMR diagnosis was based on clinical symptoms, supported by laboratory markers such as elevated CRP (85%) and ESR (90%). GCA was clinically suspected in 38 patients, with 76% confirmed through TAB. Additionally, 67% of GCA patients exhibited the "halo sign" on vascular ultrasound, while 12% required magnetic resonance angiography for further evaluation. Glucocorticoid therapy was initiated in all cases, leading to clinical remission in 84% of patients. However, 28% developed hyperglycemia, and 14% experienced osteoporosis as treatment-related complications. Delayed glucocorticoid initiation caused a significantly higher relapse rate (p = 0.04).
conclusionsGlucocorticoid therapy remains effective in most cases, though adverse effects necessitate careful monitoring. Tocilizumab was required in 18% of patients due to glucocorticoid resistance or intolerance, but it caused higher relapse rates and metabolic complications. The findings emphasize the need for steroid-sparing therapies and personalized treatment approaches to improve long-term disease control. Future research should explore newer biologic treatments, optimize imaging strategies, and address resource limitations to enhance early detection and management outcomes in elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.